Truepill, the startup behind direct-to-consumer health brands like Hims and Nurx, plans to expand into lab testing. The startup raised $75 million in a series C funding round.

Today, the company said that it had raised $25 million from Optum Ventures (the venture fund of Optum Health), Initialized Capital, TI Platform Fund, Sound Ventures and others, bringing Truepill’s total funding to $39 million at a valuation that Forbes estimates at nearly $300 million.